To advance new cryopreservation technology, San Antonio-based BioBridge Global has partnered with Australian BioTech company Vitrafy Life Sciences and will develop advanced systems addressing human blood services and cellular therapies. The agreement looks to revolutionize the cryopreservation industry and offer supply chain solutions to mitigate blood shortages in the U.S. and globally.
The partnership will develop protocols and methodologies using Vitrafy’s patented algorithm and will support tech innovation designed to improve the survival rates of blood and blood products during the cryopreservation supply chain process. The technology will also advance cellular therapies such as CAR T-cell therapy, which have historically signified high manufacturing costs with low survival rates.
“This innovative technology aligns with BioBridge Global’s mission of saving and enhancing lives through the healing power of cells and tissues by enhancing the cold chain solution for a wide range of our products,” Dr. Rachel Beddard, Senior Vice President, and Chief Medical Officer at BioBridge Global said in a press release.
Vitrafy was launched in 2018 and has become a leader in biotechnology offering innovative new patient-oriented outcomes using its complex patented algorithm, and providing consistent cryopreservation cold chain solutions. Vitrafy, in tandem with BioBridge, will work to offer optimization of life-saving therapies.
The collaboration comes at an optimal time to address the lag in industry innovation, “cryopreservation supply chains haven’t seen technological advancements for decades,” Vitrafy Co-founder Brent Owens said. “A post-COVID world needs better systems in place to ensure that a constant supply of blood products is always available for patients in need.”
To learn more about the recently announced collaboration, or for more information on BioBridge Global and Vitrafy Life Sciences, and their respective advancements in the field of biotechnology, view the press release from BioBridge Global.